FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter.
作者信息
Trinh Jonathan Q, Ellithi Moataz, Shonka Nicole, Bergan Raymond C
机构信息
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
出版信息
Clin Cancer Res. 2023 Feb 1;29(3):684. doi: 10.1158/1078-0432.CCR-22-2968.
Abstract
摘要
相似文献
1
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter.美国食品药品监督管理局批准摘要：用于VHL病肿瘤的贝佐蒂凡——信函
Clin Cancer Res. 2023 Feb 1;29(3):684. doi: 10.1158/1078-0432.CCR-22-2968.
2
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response.美国食品药品监督管理局批准摘要：贝佐蒂凡用于治疗VHL病肿瘤——疗效
Clin Cancer Res. 2023 Feb 1;29(3):685. doi: 10.1158/1078-0432.CCR-22-3428.
3
Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.贝伐珠单抗在一名 VHL 相关性转移性胰腺神经内分泌瘤患者中的应用。
J Natl Compr Canc Netw. 2022 Dec;20(12):1285-1287. doi: 10.6004/jnccn.2022.7047.
4
Belzutifan: A Narrative Drug Review.贝伐珠单抗：一种叙述性药物评价。
Curr Drug Res Rev. 2022;14(2):88-95. doi: 10.2174/2589977514666220401094724.
5
Molecular-genetic diagnostics of von Hippel-Lindau syndrome (VHL) in Bulgaria: first complex mutation event in the VHL gene.保加利亚冯·希佩尔-林道综合征（VHL）的分子遗传学诊断：VHL基因中的首例复杂突变事件
Int J Neurosci. 2018 Feb;128(2):117-124. doi: 10.1080/00207454.2017.1372436. Epub 2017 Sep 13.
6
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.FDA 批准概要：贝伐珠单抗用于 von Hippel-Lindau 病相关肿瘤。
Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054.
7
Von Hippel-Lindau disease: a single gene, several hereditary tumors.冯·希佩尔-林道病：一个基因，多种遗传性肿瘤。
J Endocrinol Invest. 2018 Jan;41(1):21-31. doi: 10.1007/s40618-017-0683-1. Epub 2017 Jun 6.
8
Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene.椎管外血管母细胞瘤：10例临床病理研究及VHL基因分子分析
Pathol Res Pract. 2018 Aug;214(8):1156-1165. doi: 10.1016/j.prp.2018.05.007. Epub 2018 May 29.
9
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.靶向散发性和 Von Hippel-Lindau 综合征相关肾细胞癌中的缺氧诱导因子通路。
Crit Rev Oncol Hematol. 2022 Aug;176:103750. doi: 10.1016/j.critrevonc.2022.103750. Epub 2022 Jun 18.
10
De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.在一名具有轻度临床表型的冯·希佩尔-林道病患者中检测到新发的VHL种系突变。
J Neurosurg. 2014 Aug;121(2):384-386. doi: 10.3171/2014.2.JNS131190. Epub 2014 Mar 28.
引用本文的文献
1
Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastoma.在与希佩尔-林道（VHL）病相关的成血管细胞瘤患者中，开始使用贝佐替凡后不久发生致命性颅内出血。
ESMO Open. 2025 May;10(5):105109. doi: 10.1016/j.esmoop.2025.105109. Epub 2025 May 16.
2
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.贝伐珠单抗治疗 von Hippel-Lindau 病相关中枢神经系统血管母细胞瘤患者（LITESPARK-004）：一项多中心、单臂、2 期研究。
Lancet Oncol. 2024 Oct;25(10):1325-1336. doi: 10.1016/S1470-2045(24)00389-9. Epub 2024 Sep 13.
3
A 23-year bibliometric analysis of the development of global research on hereditary renal carcinoma.一项关于遗传性肾癌全球研究发展的23年文献计量分析。
Front Oncol. 2024 Jun 3;14:1364997. doi: 10.3389/fonc.2024.1364997. eCollection 2024.
本文引用的文献
1
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.FDA 批准概要：贝伐珠单抗用于 von Hippel-Lindau 病相关肿瘤。
Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054.
2
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.贝伐珠单抗治疗 von Hippel-Lindau 病相关肾细胞癌
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
3
Risk of hemorrhage in hemangioblastomas of the central nervous system.中枢神经系统血管母细胞瘤的出血风险。
Neurosurgery. 2005 Jul;57(1):71-6; discussion 71-6. doi: 10.1227/01.neu.0000163250.71951.18.
Zotero 插件